Anti-talen antibodies and uses thereof
AssigneeAllogene Therapeutics, Inc.
InventorsThomas Charles PERTEL, Barbra Johnson SASU
Life of this patent
Estimating the term…
Abstract
The present disclosure provides, among other things, antibodies for detecting TALENs and/or FokI nucleases in a sample and methods of using the same.
Claims25
An anti-TALEN antibody comprising a variable heavy chain amino acid sequence that is at least 85% identical to SEQ ID NO:
- 3 and a variable light chain amino acid sequence that is at least 85% identical to SEQ ID NO:
- 7, wherein the anti-TALEN antibody optionally is humanized.
2-3. (canceled)
5-8. (canceled)
(canceled)
12-15. (canceled)
An anti-TALEN antibody, comprising
- (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO:12;
- (b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO:
- 15;
- (c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO:
- 21;
- (d) a VL CDR1 comprising the amino acid sequence of SEQ ID NO:
- 22;
- (e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO:
- 23;
- and
- (f) a VL CDR3 comprising the amino acid sequence of SEQ ID NO:
- 26,
- and optionally
- (g) a VH comprising the amino acid sequence of SEQ ID NO:
- 3;
- and
- (h) a VL comprising the amino acid sequence of SEQ ID NO:
- 7,
- or comprising
- (i) a VH CDR1 comprising the amino acid sequence of SEQ ID NO:
- 12;
- (j) a VH CDR2 comprising the amino acid sequence of SEQ ID NO:
- 16;
- (k) a VH CDR3 comprising the amino acid sequence of SEQ ID NO:
- 21;
- (l) a VL CDR1 comprising the amino acid sequence of SEQ ID NO:
- 22;
- (m) a VL CDR2 comprising the amino acid sequence of SEQ ID NO:
- 24;
- and
- (n) a VL CDR3 comprising the amino acid sequence of SEQ ID NO:
- 27,
- and optionally
- (o) a VH comprising the amino acid sequence of SEQ ID NO:
- 3;
- and
- (p) a VL comprising the amino acid sequence of SEQ ID NO:
- 8,
- or comprising
- (q) a VH CDR1 comprising the amino acid sequence of SEQ ID NO:
- 13;
- (r) a VH CDR2 comprising the amino acid sequence of SEQ ID NO:
- 16;
- (s) a VH CDR3 comprising the amino acid sequence of SEQ ID NO:
- 21;
- (t) a VL CDR1 comprising the amino acid sequence of SEQ ID NO:
- 22;
- (u) a VL CDR2 comprising the amino acid sequence of SEQ ID NO:
- 25;
- and
- (v) a VL CDR3 comprising the amino acid sequence of SEQ ID NO:
- 26,
- and optionally
- (w) a VH comprising the amino acid sequence of SEQ ID NO:
- 4;
- and
- (x) a VL comprising the amino acid sequence of SEQ ID NO:
- 9,
- or comprising
- (y) a VH CDR1 comprising the amino acid sequence of SEQ ID NO:
- 12;
- (z) a VH CDR2 comprising the amino acid sequence of SEQ ID NO:
- 15;
- (aa) a VH CDR3 comprising the amino acid sequence of SEQ ID NO:
- 21;
- (bb) a VL CDR1 comprising the amino acid sequence of SEQ ID NO:
- 22;
- (cc) a VL CDR2 comprising the amino acid sequence of SEQ ID NO:
- 24;
- and
- (dd) a VL CDR3 comprising the amino acid sequence of SEQ ID NO:
- 28,
- and optionally
- (ee) a VH comprising the amino acid sequence of SEQ ID NO:
- 5;
- and
- (ff) a VL comprising the amino acid sequence of SEQ ID NO:
- 10,
- or comprising
- (gg) a VH CDR1 comprising the amino acid sequence of SEQ ID NO:
- 12;
- (hh) a VH CDR2 comprising the amino acid sequence of SEQ ID NO:
- 17;
- (ii) a VH CDR3 comprising the amino acid sequence of SEQ ID NO:
- 21;
- (jj) a VL CDR1 comprising the amino acid sequence of SEQ ID NO:
- 22;
- (kk) a VL CDR2 comprising the amino acid sequence of SEQ ID NO:
- 24;
- and
- (ll) a VL CDR3 comprising the amino acid sequence of SEQ ID NO:
- 27,
- and optionally
- (mm) a VH comprising the amino acid sequence of SEQ ID NO:
- 6;
- and
- (nn) a VL comprising the amino acid sequence of SEQ ID NO:
- 11,
- or comprising
- (oo) a VH CDR1 comprising the amino acid sequence of SEQ ID NO:
- 12;
- (pp) a VH CDR2 comprising the amino acid sequence of SEQ ID NO:
- 15;
- (qq) a VH CDR3 comprising the amino acid sequence of SEQ ID NO:
- 21;
- (rr) a VL CDR1 comprising the amino acid sequence of SEQ ID NO:
- 22;
- (ss) a VL CDR2 comprising the amino acid sequence of SEQ ID NO:
- 24;
- and
- (tt) a VL CDR3 comprising the amino acid sequence of SEQ ID NO:
- 27,
- and optionally
- (uu) a VH comprising the amino acid sequence of SEQ ID NO:
- 3;
- and
- (vv) a VL comprising the amino acid sequence of SEQ ID NO:
- 8,
- or comprising
- (ww) a VH CDR1 comprising the amino acid sequence of SEQ ID NO:
- 12;
- (xx) a VH CDR2 comprising the amino acid sequence of SEQ ID NO:
- 16;
- (yy) a VH CDR3 comprising the amino acid sequence of SEQ ID NO:
- 21;
- (zz) a VL CDR1 comprising the amino acid sequence of SEQ ID NO:
- 22;
- (aaa) a VL CDR2 comprising the amino acid sequence of SEQ ID NO:
- 25;
- and
- (bbb) a VL CDR3 comprising the amino acid sequence of SEQ ID NO:
- 26,
- and optionally
- (ccc) a VH comprising the amino acid sequence of SEQ ID NO:
- 4;
- and
- (ddd) a VL comprising the amino acid sequence of SEQ ID NO:
- 9.
17-29. (canceled)
A method of determining the presence or absence of a TALEN protein in a sample, comprising contacting the sample with an anti-TALEN antibody conjugated to a detectable label and determining the presence or absence of the TALEN protein in the sample.
Dependencies are inferred from the claim text.